VKTX analyst estimates
Viking Therapeutics (VKTX) analyst ratings, the average price target and its range, and every firm's latest call.
VKTX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 29, 2026 | Goldman Sachs | Viking Therapeutics price target lowered to $34 from $38 at Goldman Sachs | $34.00 |
| Oct 7, 2026 | Truist Financial | Viking Therapeutics price target lowered to $85 from $87 at Truist | $85.00 |
| Sep 23, 2026 | Truist Financial | Viking Therapeutics price target raised to $87 from $83 at Truist | $87.00 |
| Sep 22, 2026 | Oppenheimer | Viking Therapeutics price target raised to $120 from $100 at Oppenheimer | $120.00 |
| Sep 21, 2026 | Oppenheimer | Oppenheimer Reiterates Outperform Rating on Viking Therapeutic (VKTX) | $100.00 |
| May 28, 2026 | Lake Street | Viking Therapeutics initiated with a Buy at Lake Street | $89.00 |
| May 27, 2026 | Truist Financial | Truist Securities Assumes Viking Therapeutic (VKTX) at Buy | $83.00 |
| Apr 30, 2026 | Cantor Fitzgerald | Viking Therapeutics price target lowered to $100 from $105 at Cantor Fitzgerald | $100.00 |
| Apr 30, 2026 | Morgan Stanley | Viking Therapeutics price target lowered to $95 from $99 at Morgan Stanley | $95.00 |
| Mar 12, 2026 | Jefferies | Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX): "VKTX is in an execution mode this year" | $101.00 |
| Feb 12, 2026 | Morgan Stanley | Viking Therapeutics price target lowered to $99 from $102 at Morgan Stanley | $99.00 |
| Nov 12, 2025 | Canaccord Genuity | Viking Therapeutic (VKTX) PT Raised to $107 at Canaccord Genuity | $107.00 |
| Oct 29, 2025 | Canaccord Genuity | Canaccord starts Viking Therapeutics with Buy on obesity potential | $106.00 |
| Oct 23, 2025 | Cantor Fitzgerald | Viking Therapeutics offered 'transformative' Q3 update, says Cantor Fitzgerald | $105.00 |
| Oct 23, 2025 | Morgan Stanley | Viking Therapeutics price target raised to $102 from $98 at Morgan Stanley | $102.00 |
- 7 firms rate VKTX: 7 buy, 0 hold, 0 sell.
- The average price target is $82.00 from 4 analysts, from $34.00 to $120.00.
Updated 2026-11-03 00:02 UTC